Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE)
Evaluate apremilast efficacy across various psoriatic arthritis (PsA) manifestations beginning at week 2 in biological-naïve patients with PsA.Patients were randomised (1:1) to apremilast 30 mg twice daily or placebo. At week 16, patients whose swollen and tender joint counts had not improved by ≥10...
Сохранить в:
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | английский |
| Опубликовано: |
2018
|
| Online-ссылка: | https://doi.org/10.1136/annrheumdis-2017-211568 https://ard.bmj.com/content/annrheumdis/77/5/690.full.pdf |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|